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This issue of the journal contains two important multi-centre trials which address the design of treatment for small
cell lung cancer (SCLC). It is generally recognised that aggressive therapeutic regimes yield the best response rates
and therefore the highest percentage of long-term disease-free survivors in this disease (Seifter &Ihde, 1988; Holoye
& Kalbfleisch, 1984). In many reported series standard therapies have produced around 80% objective response
rates in all stages of SCLC. In patients with limited disease 50-60% may achieve a complete response (CR) with a
consequent median survival between 12 and 16 months. For extensive disease the CR rate is approximately half
with a median survival of between 7 and 12 months. Among patients with limited disease 15-20% may survive 2
years whereas very few with extensive disease will survive this long (Seifter &Ihde, 1988; Aisner et al., 1983). Thus
the population of patients with small cell lung cancer is heterogeneous and comprises subgroups with very different
potentials for long-term survival (Osterlind et al., 1983). However, all patients have a substantial chance of
symptomatic improvement provided by optimal chemotherapeutic response. Although combinations of active drugs
in small cell are superior to single agent therapy in producing good quality remissions and long-term survival
(Lowenbraun et al., 1979; Einhorn et al., 1978; Jackson & Case, 1986) there is little evidence to support the use of
more than three or four drugs simultaneously. What is very uncertain in all the studies is how long chemotherapy
should be administered. In different ways both of the studies presented in this journal attempt to address the
question of duration of therapy using standard combination chemotherapy. The CRC study (Spiro et al.) is
somewhat complex and addresses two issues, one being an attempt to gauge the optimum duration of initial therapy
and the other ascertaining the added benefit, if any, of different chemotherapy for relapsed disease. In the MRC
study (Bleehen et al.) the randomisation is a simple comparison of the value of six versus 12 courses of
chemotherapy, the extra six courses given in a randomised fashion as maintenance therapy for individuals still
responding after six cycles of initial treatment.
In the CRC study 610 patients were randomised to receive either four or eight courses of combination
chemotherapy. Entry criteria were permissive and the study was likely to include many old andfrail patients.
Staging tests were limited to biochemical assessment, chest X-rays and bone scans. Nevertheless, the population of
patients thus collected comprised an apparently appropriate ratio of 196 patients with limited disease
(approximately 1/3) against 414 patients with extensive disease (approximately 2/3). The response rate to four
courses of initial chemotherapy was 61% and did not improve in the cohort receiving eight courses, being 63% after
the extra therapy. Response rates to relapse chemotherapy were low, being 25.6% for patients who had received
four courses of initial therapy against 18.7% for those who had received eight. The overall survival, however, was
apparently compromised for patients who received only four courses of induction and no relapse therapy, being 30
weeks median against the other three treatment options, in which patients had a median survival of 39 weeks. This
was particularly marked in patients who had responded to initial chemotherapy. The study indicates that limiting
treatment to a total of four courses of chemotherapy is associated with inferior survival, with responsive patients
being particularly disadvantaged.
In the MRC trial 497 patients were randomised to four-drug combination therapy and the patients with limited
disease (who surprisingly comprised 74% of the total) received additional radiotherapy between courses 2 and 3. At
the end of the initial therapy patients still responding were randomly allocated to no maintenance or to 6 further
courses of maintenance therapy, comprising the same drugs at slightly longer (4-week) intervals. The overall
response rate to initial therapy was 66% and the median survival for all patients from the start of chemotherapy
(identical to the CRC study) was 39 weeks. The paper reports the survival at 1 and 2 years at 31% and 6%
respectively. There was no overall survival benefit for patients receiving maintenance therapy although in 99
patients who had a complete response to initial therapy there was a suggestion of longer survival in the maintenance
therapy arm, 42 weeks median from the date of randomisation against 30 weeks for those not given maintenance
therapy. An attempt was made to assess quality of survival - the toxicity and subjective impact of treatment
assessed by physicians and patients suggested that maintenance therapy was associated with poorer quality of life.
No worthwhile survival advantage was achieved by the policy of continuing treatment beyond six treatments except
possibly in patients who had obtained a complete clinical remission after induction therapy.
Both studies, being large and multicentre and therefore permissive for patient entry to their protocols, are open to
criticism in their design, execution and analysis. In the CRC study there was a double randomisation of treatment
at presentation with stratification by extent of disease. This design represented a modification of the original
protocol, which had been to perform two separate randomisations. However, the initial design began to fail 3
months into the trial when 26 patients were not randomised because of the clinicians' reluctance or because of
refusal by patient to accept relapse therapy. Since the aim of the trial was to assess different treatment policies, the
trial design was altered and all subsequent patients were randomised for initial and relapse therapy at entry so that
analyses were based therefore upon treatment intent. Although response did not affect the subsequent
randomisation decisions, it should be recognised that analysis of reponse was outside the standard UICC guidelines
and comprised minimal investigations in its assessment. The statistical design of the study seemed to be adequate,
with a high power of detecting a 10% difference in survival at 1 year. However, since the 1-year survival was not
given we cannot be certain whether this aim was achieved. Although the overall response rate to eight courses was
not superior to four, the proportion of complete responders did increase (with the caveat that assessment of
response status was inadequate). The documentation of relapse chemotherapy bore out the suspicion of the
experience of the first 3 months of the trial, namely that a high proportion of patients randomised to relapse
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chemotherapy failed actually to receive it. Thus 54/144 patients (37.5%) of patients who had received short course
chemotherapy failed to receive their allocated relapse treatment and 70/160 patients (43.75%) who had received long
course induction failed to receive relapse therapy. Reasons were consistent regardless of whether the patient had
been given short or long course treatment, in one-third of cases death during initial therapy but in two-thirds of
cases medical contra-indications, patient refusal and other complications. Comparing induction therapy strategies of
short versus long, in terms of progression-free interval there seemed to be an advantage for patients who had
received longer course initial treatment. It is not stated but can be calculated that, in terms of time off all treatment
to relapse, there seemed rather to be an advantage for those patients who had received short course therapy - 11
weeks off drugs compared to 7 weeks off drugs for those who had been on long course treatment. Conflicting
conclusions can therefore be drawn from two alternative ways of looking at progression-free interval but one
interpretation may be that at least one month of therapy on the long course treatment is ineffective and simply
provides toxicity without prolonging disease control. When the analysis was limited to the patients who had
responded to initial treatment the disadvantage of giving four courses of chemotherapy alone was even more
apparent and a survival difference between this and the other treatment groups was apparently still present at 2
years. The actual survival data are not given. The analysis does not then address the problem of the patients who
did not respond to initial treatment. One must presume that some of the survival advantage which was additionally
seen in the responding population was reversed by a survival disadvantage for the non-responders, who must by
definition have been overtreated. Toxicity analysis was sketchy and indicated little more than the observation that
most patients appeared to receive adequate drug doses. The authors commented that many patients progressed
during initial chemotherapy and the clinicians in charge sometimes felt that a patient became too unwell to resume
relapse chemotherapy. They stated that patients dropping out of study were more likely to be those with poor
performance status and/or extensive disease, although this was not demonstrated in the analysis. Given the rate of
failure to complete second line therapy, it is difficult to argue with the conclusion that treatment ofrelapse is harder
to realise with longer induction therapy.
In the MRC trial, selection of patients was again very permissive, all patients with histologically or cytologically
confirmed disease were considered unless there was a specific contra-indication to chemotherapy or radiotherapy.
Pretreatment investigations were again minimal, comprising a chest X-ray and blood examination, following which
patients were allocated to the prognostic categories of limited or extensive disease on slightly more generous criteria
than the CRC trial but insufficient to explain the enormous difference between the studies in the ratios of limited to
extensive disease. Thus 74% of the 497 patients ostensibly had limited stage disease in this trial. Laudably, an
attempt was made to assess initial chemotherapy response induction early and 85% of 265 patients assessed after
two treatment courses were apparently responding although only 11% had complete remission. In spite of this high
initial response rate, and the application of chest irradiation for patients with limited disease, the overall response
rate was just 66% at the end of six cycles of therapy. Again this implies that for a considerable proportion of
patients, much of the remaining induction therapy was adding little or nothing to the quality of their response. At
the end of the initial induction 128 patients had died and 41 of the patients alive were no longer responding. From
the remaining 328 patients therefore available for further randomisation to maintenance treatment, only 265
actually were randomised and the reasons for the 63 patients not randomised are never stated in the analysis. This
is a very important problem in the analysis of the paper and will remain an unanswered question in its present
published form. The authors otherwise very carefully assessed the patients who achieved randomisation
either by intent to treat or by the actual treatment delivered. Thus of the 131 patients allocated to receive
maintenance chemotherapy only 35% received it without modification. The majority therefore had treatment
modified (because of toxicity), had it stopped, or in 25% of cases never even started. At eventual relapse 159
patients received additional treatment, in the vast majority (120) of cases radiotherapy alone. Thus relapse therapy
was unlikely to have influenced the effect of maintenance versus no maintenance treatment. Follow-up for this
study was good and the usual analysis of prognostic factors at the start of treatment produced a predictable result
for the advantage of good performance status and limited stage disease. Analysis by maintenance therapy, however,
showed no advantage for continuing therapy and this remained true even when analysed by receipt of maintenance
as opposed to analysis by intent. The authors justifiably felt that this provided compelling evidence that prolonging
chemotherapy beyond six courses did not in general influence survival. On subgroup analysis, i.e. based on dividing
the 265 randomised patients into limited versus extensive disease (pretreatment) and those with partial versus
complete response to initial treatment, there was a suggestion of maintenance therapy influencing survival in those
who had had complete response to initial treatment. This result is thus similar to the effects seen for relapse therapy
in the CRC trial. A thorough analysis was performed of prognostic factors both at presentation and at the time of
randomisation, although significantly the balance of the group randomised for maintenance was not stated. Some
attempt was made to analyse time of death and cause of death in relation to chemotherapy and disease status. An
increase in death rates occurred during the second week following each cycle of treatment whether given as
induction or at maintenance. At death the majority of patients had persistence or recurrence of disease at primary
site and a large majority (79%) had distant metastases. In attempting to assess the influence of maintenance therapy
on metastases, the paper reports the outcome in patients with limited disease. Unfortunately, because of the poor
assessment of extent of disease these data may not be particularly informative. The majority of relapses at
metastatic sites occurred within six months of randomisation and probably reflected understaging from the very
start. Toxicity analysis again tends to suggest adequate doses of drugs were delivered and in view of the current
interest in intercalated radiotherapy (Arriagada et al., 1985) it is interesting to note that although platelet counts
were detectably lower, the radiation effect was not dangerous. The impact of maintenance on the quality of life was
analysed by clinicians and patients. The results seem to be congruent, demonstrating that the best categories were
.~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ -- 47 .-.- seen in patients without maintenance and the worst categories (except for mood) seen in the patients given maintenance therapy. Thus the majority of patients did not benefit from maintenance chemotherapy in this trial. The trialists are to be congratulated for attempting to assess quality of survival in a disease where, for the majority of patients, there is no prospect of long-term survival. However, there are a number of methodological problems. First, the measurement of mood and anxiety depends upon a technique that has not been evaluated, even though a number of well validated instruments (e.g. the simple Hospital Anxiety and Depression Scale) were available before 1983 (Zigmond & Snaith, 1983; Snaith et al., 1978). Second, the overall condition of the patients (assessed bySMALL CELL LUNG CANCER 489
clinicians who were aware of the maintenance therapy selected) is ill-defined. Third, the diary card technique for
self-assessment is unreliable as no assessment was made of the timing of card completion by patients. A tendency to
complete forms in batches rather than daily is a common problem (Peck & Dean, 1983). The concept of self-
assessment is commendable and concurs with Slevin's conclusion that a patient is the best judge of his quality of life
(Slevin et al., 1988). There was then no conclusive benefit for treatment beyond the initial six courses, toxicity
increased and the quality of life was adversely affected by prolonging treatment. However, because of the possible
benefit for patients who had a complete response to initial therapy, the MRC intends doing further analysis of
treatment duration. Again implicit from the subgroup analysis would be one conclusion that response to initial
therapy is an important method for designing maintenance or relapse treatment. Neither of these studies has
addressed this question directly but the design of therapy duration based upon initial response remains one
candidate for further study.
The MRC and CRC trials therefore show many similarities but also important differences. In respect of
treatment, the induction regimes and selection of patients appear to be very similar and produced similar toxicity.
The important difference appears to be in relation to chest irradiation, which although not stated is assumed not to
have been used in the CRC study. The impact of thoracic irradiation upon the duration and quality of response is
difficult to determine because of the different duration of therapies and slight differences in the drugs chosen
compared with the CRC trial. The similarities in response rates at the end of induction therapy suggest that the
impact of the different treatment approach is minor in these populations of patients. Whether the populations of
patients themselves are very different is open to question. On the face of it the differences in the incidences of
limited and extensive disease of the two studies are very striking but again given the usual prognostic importance of
limited extent of disease (confirmed in these studies) one would have expected a difference in the average survival
between the two populations which in fact is not seen. It can only be concluded that a considerable proportion of
patients with 'limited disease' in the MRC study would have been classified as extensive disease had they been more
conventionally investigated, even by the modest demands of the CRC protocol. The lack of late follow-up in the
CRC study is disappointing, particularly in view of the statistical constraints which demanded the large numbers of
patients entered because of the intent to detect specific survival differences at 12 months from entry. Both studies
avoid the pitfall of over-interpreting and over-analysing their data. To an extent, however, this can be seen as a
criticism in that there are unexplained gaps in the analysis, particularly in the MRC study where 63 patients were
simply not considered further although they should have been eligible for maintenance therapy randomisation.
Likewise in the MRC study the prognostic balance of the randomised groups in relation to extent of disease and
performance status at randomisation is unstated. Problems with both studies are seen in the lack of care applied to
staging, in which the protocol instructions were vague, resulting in the potential for variability from centre to
centre. Radiotherapy is not discussed throughout the CRC paper and in contrast to the MRC study, the issue of
toxicity of therapy is rather under-evaluated.
The two trials presented thus partially addressed the problem of therapy duration. The general conclusion that
prolonging therapy does not improve quality or duration of survival is a common finding but both studies were
unable to point to an optimum duration of therapy and were also unable to identify the patients (whose disease was
basically chemosensitive) who probably would benefit from prolonged therapy. Neither paper concludes, however,
that the adoption of a flexible response type design to duration of therapy might be one way of identilying these
patients. Generally (demonstrably in the MRC study) most patients ultimately relapse with metastatic disease.
The alternative idea of treating aggressively a smaller tumour burden in chemosensitive patients has unfortunately
proved to be a disappointing strategy. Identifying patients most likely to benefit by virtue of prior response,
selecting a patient group with a minimum treatment burden and treating them at a time when they are physically
well would in theory seem to be an ideal set of circumstances for a disease such as SCLC. However, in the nine
published trials of late intensification the overall results were disappointing (Klastersky et al., 1982; Stewart et al.,
1983; Cunningham et al., 1985; Smith et al., 1985; Sculier et al., 1985; Spitzer et al., 1986; Ihde et al., 1986;
Humblet et al., 1985; Cornbleet et al., 1984). There were problems of design with all the published studies and
probably too often agents (particularly alkylating agents) were employed in late intensification that had already
been scheduled in the induction regime (Livingston, 1986). Apart from design errors, the issue of the essentially
systemic nature of the disease was probably insufficiently considered. With increasingly sophisticated methods for
tumour detection it is now becoming recognised that the vast majority of patients, whether or not conventionally
presenting with limited stage disease, usually have systemic disease. This is substantiated by the eventual patterns of
progression as well as by the long observed phenomenon that the only treatment with any survival impact in this
disease has been systemic therapy (Green et al., 1969; Smyth et al., 1986)). Although additional loco-regional
therapy therefore needs to be considered to improve control of primary tumour, there is a real possibility in the
autologous marrow rescue programmes that infusing explanted marrow allowed the introduction of viable
clonogenic tumour stem cells (Leonard et al., 1988; Hay et al., 1988). Future programmes which address late
intensification of treatment as opposed to maintenance therapy should take into account this observation and
consider programmes for marrow purging.
Experimentation with chemotherapy in small cell lung cancer over the past decade has proved a frustrating
experience. The aim of curing the majority of patients with this disease using systemic therapy seemed at the start of
this decade to be a realistic goal but has at the end of it proved to be something of a mirage. At the same time as
the chemotherapy strategies have stumbled, the cell and molecular biologists have made great strides in contributing
to our understanding of this complex disease. It is the fervent wish of clinicians that insights into the biology of
SCLC will eventually point to novel treatment strategies that will materially affect the survival of the majority of
patients. Nevertheless it should be recognised that there are small numbers of patients who are potentially curable
with our current drugs. As these two studies have so well demonstrated the problem is identifying the patients at
the start who will benefit from intensive and long duration therapy. Attempts are now being made to utilise some of
the information obtained from laboratory studies in recent years and to apply, for instance, immunological
techniques to characterise the clinical tumours (Fargion et al., 1986; Stahel et al., 1985). In this way it has been
hoped that profiling tumour cells with cell markers could provide some 'window' on the biology of the disease
which would enable clinicians to predict its behaviour. Although one or two promising insights have been obtained
in relation to prognosis (Allan et al., 1987) it has to be admitted that currently the clinicians' view of small cell lung490 R.C.F. LEONARD
cancer is not so much a clear picture of the biological characteristics as a rather crude daguerrotype. It is to be
hoped that with refinement of immunohistopathology, improving our understanding of the function of the
molecules which characterise the cells in vitro, possibly by the manipulation of cell behaviour with hormones or
growth factors, a real impact can be made in the selection of products for effective therapy.
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